Second, the clinical heterogeneity of mCRPC, especially characterized by highly variable number of previous therapies, which could impair plasma AR status and clinical outcome.40 Third, the lack of next-generation imaging such as PSMA PET/CT in most enrolled patients could have led to a better definition of tumor burden. Here, FOLH1 is linked to neoplasm.